Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation

Michele Fornaro1
Matteo Martino1
Florinda Battaglia2
Salvatore Colicchio3
Giulio Perugi4

1Department of Neuroscience, Section of Psychiatry, University of Genova, Genoa, Italy; 2Center of Excellence for Biomedical Research (CeBr), Genoa, Italy; 3Department of Neurosciences, Catholic University, Rome, Italy; 4Department of Psychiatry, Institute of Behavioral Sciences, University of Pisa, Pisa, Italy

Background: Immune modifications, including changes in interleukin (IL)-6 levels, have often been observed in major depressive disorder (MDD) during treatment with selective serotonin reuptake inhibitors (SSRIs) or the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine. Nevertheless, no equivalent observation for the SNRI duloxetine has been made to date.

Method: Sixteen patients diagnosed with MDD and an actual major depressive episode according to DSM-IV criteria and 16 healthy controls entered a 6-week trial with duloxetine 60 mg/day. All subjects (n = 32) were assessed using the Hamilton Depression Rating Scale (HAM-D), the Young Mania Rating Scale (YMRS), and were monitored for IL-6 levels both at baseline and at week 6. Blood samples for IL-6 levels were evaluated by ELISA.

Results: After 6 weeks of treatment, the mean total scores for HAM-D declined both in the depressed and control groups, while IL-6 modification showed an opposite trend both in depressed (12.38 ± 19.80 to 19.73 ± 18.94 pg/mL) and control subjects (12.25 ± 21.12 to 17.63 ± 20.44 pg/mL), as did YMRS (ns), although none of the subjects switched to (hypo)mania. Of note, IL-6 levels increased significantly only in the responders subgroup (n = 9; P = 0.012).

Conclusion: The small sample size and weak design of this study limit the validity of our results, which should be regarded as preliminary only. Nonetheless, the trend of increasing IL-6 levels observed in responder patients treated with duloxetine should prompt further controlled, extended studies with larger samples, with the specific aim of better assessing a putative differential role of norepinephrinergic antidepressant stimulation of serotonergic reuptake inhibition in determining modifications in IL-6 levels. Ideally, more accurate replication studies may contribute to further understanding of the complex interaction of mood, antidepressant response, and the immune system.

Keywords: interleukin-6 (IL-6), duloxetine, major depressive disorder (MDD)

Introduction
In recent years, an increasing number of investigations have explored the relationship between immune and neuroendocrine systems and different psychiatric conditions, especially mood and anxiety disorders, with the aim of improving our understanding their etiopathology and developing more effective therapeutic management.

Neurotransmitters and hormones regulate major immune functions, such as antigen presentation, antibody production, activity, proliferation and traffic of lymphocyte, as well as the process of cytokines secretion, including modulation of T helper (Th) 1 or Th2 cytokine responses. In the course of inflammatory processes, the activation of the stress system, through induction of a Th2 shift, protects the organism from systemic “overshooting” with Th1/pro-inflammatory cytokines. Under certain
conditions, however, stress hormones and the activation of the corticotropin-releasing hormone/substance P-histamine axis may actually promote inflammation, through induction of interleukin (IL)-1, IL-6, IL-8, IL-18, tumor necrosis factor (TNF)-alpha, and C-reactive protein production. Investigations of immune imbalances in the course of major depressive disorder (MDD) have demonstrated higher serum concentration of some cytokines such as IL-6 (a Th2-type cytokine), IL-1, and TNFα (Th1 cytokines), with similar findings shown also in course of anxious states, reflecting a substantial psychopathological overlap. Recently, the need for further insights into the antidepressant efficacy of antidepressants and the need for a better understanding of the putative biological bases of depression, prompted correlational studies investigating the influence of antidepressant medications on the immune system, both in psychiatric patients and the general population, and in animals. To date, most of the immunological investigations carried out in MDD patients treated with antidepressant drugs focused on IL-6 modifications in the course of serotonergic selective serotonin reuptake inhibitors (SSRIs) treatment, which is still the most frequently prescribed class of antidepressants. Also, while most of the evidence suggests a decrease of IL-6 levels in the course of SSRIs antidepressant treatment, global results are inconclusive, thus raising questions about the relationship between serotonergic-mediated antidepressant response and IL-6 decrease. Nevertheless, corresponding data for other classes of antidepressant drugs are lacking. Only preliminary evidence is available for the effect of venlafaxine, a serotonin norepinephrine reuptake inhibitor (SNRI), on IL-6 levels during the course of MDD, with increases or decreases in IL-6 essentially governed by the dose of drug given. Venlafaxine appears to have a complex action on IL-6: administered at low doses, it appears to reduce IL-6 serum levels, but higher doses (eg, ≥150 mg/day) seem to induce an increase in IL-6. Venlafaxine essentially acts as a pro-serotonergic, SSRI-like, antidepressant at low doses, while at higher doses it also produces a pro-norepinephrineric effect. Thus, assessing the effect of venlafaxine on IL-6 should take into account the dose. Remarkably, no equivalent data have been obtained to date for duloxetine, another SNRI drug. Furthermore, duloxetine is supposed to act as a balanced (1:1), pro-serotonergic and pro-norepinephrinergic drug independently on its dosage, thus IL-6 levels upon duloxetine administration would be expected to follow a linear trend even at low doses (eg, 60 mg/day or lower).

The objective of this study was to investigate the effect of 60 mg/day duloxetine on serum concentration of IL-6 in 16 depressed outpatients and 16 healthy controls within a period of 6 weeks, with the aim of gaining a better understanding of the interaction between antidepressant response and IL-6 levels.

Method

Twenty outpatients diagnosed with MDD were screened over 12 months for inclusion in a 6-week open-label trial investigating the effect of duloxetine 60 mg/day monotherapy on IL-6 levels. All diagnoses were made according to the Diagnostic and Statistical Manual for Mental Disorders (Fourth Edition) (DSM-IV) criteria assessed by the Structured Clinical Interview for Axis-I Disorders/Patient edition (SCID-I/P). At baseline, 16 patients were eligible to enter the study (3 did not sign the informed consent and 1 was coughing), fulfilling all the inclusion criteria, including the actual presence of a single or recurrent, drug-naïve, major depressive episode, age of 18 to 65 years, and able to give a valid informed consent upon approval by the local Ethical Committee. Exclusion criteria included the following: pregnancy, breast-feeding, bipolar disorder, any anxiety disorder, schizophrenia, schizo-affective disorder, dementia, current suicidal and/or psychotic ideation, or concomitant taking of relevant nonpsychotropic medications (including other antidepressants, nonsteroidal anti-inflammatory drugs, and oral contraceptives). Any eventual concomitant medication had to be discontinued at least 15 days prior taking of duloxetine, 4 weeks earlier in case of fluoxetine or depot antipsychotics. Zolpidem 5 to 10 mg/day or diazepam 5 to 10 mg/day were allowed, but could not be taken the night before scheduled assessments. Additional exclusion criteria included history of relevant medical comorbidities (ie, autoimmune, allergic, neoplastic, endocrine diseases, surgery, vascular stroke, or acute or chronic infection within the previous month). A mandatory inclusion criterion was the presence of a baseline total score on the Hamilton Depression Scale (HAM-D) at 17 items ≥18 (responders would have to show a reduction of HAM-D score at week 6 ≥50% vs baseline) when undergoing a physical examination, standard laboratory tests, and immunological monitoring of IL-6. The Young Mania Rating Scale (YMRS) was also administered both at baseline and week 6 in order to assess any eventual drug-induced (hypo)manic switch, defined as a total score ≥13. Blood samples were obtained at 08.30–10.00 AM, in order to limit a potential circadian rhythm variance bias. The whole sample was rescreened at
week 6 (end of the study) using HAM-D and IL-6 sampling (blood samples were drawn at the same time). Serum levels of IL-6 were measured using the instant ELISA (enzyme-linked immunosorbent assay) method (Bender MedSystems, Burlingame, CA). The same clinical rating scales and laboratory procedures were also applied to the healthy control group (n = 16) defined by a baseline HAM-D score <7 and YMRS < 12. All laboratory procedures were performed at the San Martino Hospital of Genoa, Italy. Over the entire trial, the control group received exactly the same pharmacological regimen (duloxetine 60 mg/day) prescribed to the depressed subjects.

Statistical analysis
The investigated sample included a low number of subjects. Baseline and week 6 HAM-D and IL-6 variables did not follow a normal distribution according to the Kolmogorov–Smirnov test, therefore requiring nonparametric tests for the comparison of groups in order to assess the hypothetical validity of IL-6 biomarker for antidepressant response to duloxetine. IL-6 levels of responders, nonresponders, and controls were compared using the Mann–Whitney U test.

Pre- and post-treatment IL-6, HAM-D, and YMRS values of the depressed patients and healthy controls were assessed using the Wilcoxon paired samples test. Correlation between IL-6 levels and HAM-D values between responders, nonresponders, and control was assessed using the Pearson correlation coefficient. Two-tailed tests with a 5% level of significance were used throughout the analyses. All statistical analyses were performed using IBM SPSS Statistics® Version 19 for Windows® (SPSS, Chicago, IL).

Results
The sample (female, F = 21; male, M = 11) included 16 MDD patients (F = 12; M = 4) with a mean baseline HAM-D = 20.94 ± 2.839 and YMRS = 2.12 ± 1.15 and 16 healthy controls (F = 9; M = 7) with a mean HAM-D total score = 3.75 ± 1.44 and mean YMRS = 4.7 ± 2. Mean ages of patients and controls were 51.1 ± 11 and 44 ± 11.6 years, respectively. No statistically significant differences were observed between the groups for gender distribution, age, or baseline HAM-D (although, by definition, this was higher in patients vs controls). Comparison of mean values of HAM-D and YMRS total scores and IL-6 mean values before and after the treatment in the depressed patients at baseline and control subjects are reported in Table 1. In the patients group, 14 patients (87.5%) showed a reduction in HAM-D total scores after treatment while 2 (12.5%) were unmodified; IL-6 levels increased in 11 patients (68.75%) and decreased in 5 (31.25%). Notably, in the patients group all clinical modifications in the follow-up observation were significant (P = 0.001), but in the nonresponders none of the changes in IL-6 levels were significant. In the control group, 6 (37.5%) subjects showed a reduction in HAM-D scores, 3 (18.75%) had an increase, and 7 (43.75%) were unmodified. Six (37.5%) subjects reported an increase in YMRS score, 6 (37.5%) a reduction, while 2 (12.5%) were unmodified. Eight (50%) patients showed a reduction in IL-6 levels, 6 (37.5%) an increase, and 2 (12.5%) were substantially stable. Notably, none of the modifications observed in the control group was statistically significant, including differences in baseline IL-6 levels between patients and controls. No statistically significant correlations between HAM-D, YMRS scores, and IL-6 levels among responders, nonresponders and controls, before and after treatment, were observed except for the IL-6 levels pre- and post-treatment in responders (P = 0.012), as shown in Table 2. The HAM-D (P = 0.001) and the YMRS (P = 0.001) mean total scores pre- and post-treatment were significantly different between baseline and week 6 in the patients group. No statistical correlations were observed between HAM-D and IL-6 scores at baseline in any group. Finally, none of the subjects enrolled in the study experienced adverse events or significant side effects (eg, nausea, headache) that could be considered as physiological stressors that could have influenced the hypothalamic–pituitary–adrenal axis and directly or indirectly affected IL-6 levels.

Table 1 Mean values of HAM-D and YMRS total scores and IL-6 mean values before and after the treatment in the depressed patients at baseline and control subjects

<table>
<thead>
<tr>
<th></th>
<th>HAM-D total score (mean ± SD)</th>
<th>YMRS total score (mean ± SD)</th>
<th>IL-6 levels (pg/mL) (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-treatment</td>
<td>Post-treatment</td>
<td>Pre-treatment</td>
</tr>
<tr>
<td>Patients (n = 16)</td>
<td>20.94 ± 2.84</td>
<td>9.13 ± 5.8</td>
<td>2.13 ± 1.15</td>
</tr>
<tr>
<td>Controls (n = 16)</td>
<td>3.75 ± 1.44</td>
<td>3.5 ± 1.34</td>
<td>4.69 ± 2.02</td>
</tr>
</tbody>
</table>

Notes: In the patients group, the modifications in HAM-D and YMRS scores were highly significant (P = 0.001) but those in IL-6 levels were not (P = 0.215). In the control group, there were no significant modifications: HAM-D (P = 0.248), YMRS (P = 0.968) and IL-6 (P = 0.775).

Abbreviations: HAM-D, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale; IL-6, interleukin-6.
Table 2 Modification in interleukin (IL)-6 levels before and after treatment in the responders group ($P = 0.012$) and nonresponders (ns)

<table>
<thead>
<tr>
<th>IL-6 levels (pg/mL) (mean ± SD)</th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responder patients ($n = 9; 56%$)</td>
<td>$6.89 ± 6.878$</td>
<td>$40.43 ± 20.32$</td>
</tr>
<tr>
<td>Nonresponders ($n = 7; 44%$)</td>
<td>$19.45 ± 28.523$</td>
<td>$18.83 ± 18.566$</td>
</tr>
</tbody>
</table>

Discussion

A number of issues should be considered in the interpretation of our results, which should be considered only preliminary at this time. The open design method of the study and its lack of power, the lack of an accurately matched control group, the unrepresentative sample size, and short follow-up significantly limit the validity of our findings. Additionally, IL-6 serum levels measured during the study might differ from those beyond the blood–brain barrier. Nevertheless, IL-6 levels are “dispersive” in terms of standard deviation even in baseline samples, both in depressed and control subjects, further limiting the statistical validity of our results. Additionally, the unexpected finding of a general increase in IL-6 levels after a 6-week treatment with duloxetine 60 mg/day in responders compared with available data for SSRIs, the lack of larger sampled control groups including other classes of drugs, and/or additional arms with higher dosages of duloxetine (eg, 120 mg/day) appear relevant, too.

After 6 weeks of treatment with duloxetine 60 mg/day, all subjects (both patients and controls) showed a decrease in HAM-D total scores and a slight increase in YMRS scores. None of the patients switched to mania according to YMRS cut-off. Nine of 16 patients had a preliminary response (actually a clinical “remission”) and a significant increase in IL-6 levels after 6 weeks.

Although the small sample size of this study might have contributed to almost the lack of statistically significant results, it should be noted that the increase in IL-6 levels after 6 weeks treatment with duloxetine 60 mg/day in responders is an unexpected result. Indeed, the evidence for a modification in IL-6 levels in MDD is still a debated issue. In a pioneering study Maes et al, higher levels of IL-6 levels were observed in patients with MDD vs controls. Berk et al also found significantly higher levels of IL-6 in patients with MDD. On the contrary, Kagaya et al found no significant difference in IL-6 levels of depressed patients compared with healthy subjects.

Additionally, Levine et al found decreased levels of IL-6 in the cerebrospinal fluids of depressive patients, while in a study by Kubera et al, serum IL-6 levels of depressed patients were higher compared with healthy controls. However, this difference was not statistically significant and the IL-6 levels of treated patients did not decrease upon recovery from depression. Lanquillon et al found an increase in mean IL-6 levels of responders after antidepressant treatment, while it remained high in nonresponders. Frommberger et al found a decrease in the IL-6 levels of depressed patients after treatment with antidepressants. De Berardinis et al, in a systematic review of immunological modulation in the course of antidepressant therapy, including venlafaxine, found that IL-6 levels decreased at low doses (as generally observed in course of treatment with SSRIs), and increased at higher doses. This may be hypothetically due to a differential serotonin/norepinephrine (5-HT/NA) balance caused by the drug, depending on its dosage. Indeed, both 5-HT and NA appear implicated in IL-6 modulation.

These evidences suggested the investigation of duloxetine impact on IL-6 levels, focusing on its pro-norepinephrinergic properties, especially considering that current literature data on other (also) pro-norepinephrinergic drugs is almost unavailable. Specifically, in relation to levels of cytokines and their modulation after treatment with tricyclic antidepressants (TCAs), some studies showed that this class of drugs inhibits the IL-1β, IL-2, TNF-alpha, and INF-γ (Th1-type cytokines) and may enhance the production of IL-10 (Th2-type cytokines). Yet, studies on TCAs and IL-6 show discordant results: while a clinical study reported an increase in IL-6, other preclinical investigations do not. Furthermore, while TCAs may significantly differ from each other in terms of prevalent stimulation (eg, tertiary amines may promote 5-HT stimulation while secondary ones may enhance the NA-ergic transmission), the investigation of the effect of TCAs on IL-6 levels appears further complicated by the fact that these compounds have a wide range of pharmacodynamic effects. Among other effects, TCAs show muscarinic (M1), adrenergic (alpha-1), and histaminergic (H1) blockade, potentially affecting the immune modulation. Also, it should be noted that desipramine, a secondary amine, inhibits TNF-alpha production, increasing the release of IL-10 and shifting the immune balance toward a Th2-like response. Regrettably, no equivalent data are available for most of the newer pro-NA-ergic antidepressants such as atomoxetine, or the studies did not focus on IL-6, as in the reboxetine nonclinical studies. However, a single study in animal cells and under specific conditions, reported that pretreatment with reboxetine inhibited the increase of IL-6 due to INF-gamma exposure in the murine microglial cells. Anyway, it should be remarked that the disparity of results from pre-clinical vs clinical studies might be due to dose
and timing issues, further requiring rigorous investigations focusing on glucocorticoid–catecholamine interactions.

Recent evidence indicated that both glucocorticoids and catecholamines (epinephrine and NA) systematically mediate a Th2 shift suppressing role on Th1 cytokine (IL-12 and IFN-gamma) and upregulation of Th2 cytokine production (IL-6 and IL-10) through stimulation of cytoplasmic–nuclear glucocorticoid receptors and β2 adrenergic receptors, respectively. Therefore, since catecholamines upregulate IL-6 production, the chronic hyper-noradrenergic state, essentially promoted by NA-ergic stimulation, may drive the increase in systemic IL-6 levels.

Interestingly, baseline IL-6 levels in patients in treatment remission after 6 weeks were considerably higher than in those ending treatment as nonresponders. Nonetheless, since our samples were not statistically representative and ranges of IL-6 levels are very wide, prudence is needed in interpreting our results. Nonetheless, it should be hypothesized that depressed patients who will remit on 60 mg/day duloxetine for 6 weeks (clinically indistinguishable at baseline from those who will not) may exhibit lower levels of IL-6 at baseline which in turn may “predict” a favorable response to treatment with duloxetine 60 mg/day for 6 weeks. It could be therefore hypothesized that the presence of lower levels of IL-6 at baseline among depressed (but not healthy controls) may be due to hypo-noradrenergic activity which may preferentially benefit from the pro-norepinephrinergic action induced by duloxetine, which in turn may “normalize” the IL-6 levels in this subgroup via Th2 shift mediated by NA. Indeed, much prudence as well as larger-sample controlled studies, including proxy measurements of sympathetic–nepinephrinergic activity at baseline and endpoint are warranted prior to extending such hypothesis. Nonetheless, similar findings were already reported by Lanquillon et al. regarding pre- and post-treatment IL-6 levels among responders and nonresponders. In this study, the authors found that subjects beginning the treatment in presence of lower baseline IL-6 levels were less prone to significant increase for this parameter after the trial, resembling our finding in that regard, thus suggesting that IL-6 levels “might dichotomize the patients into subsequent responders and nonresponders” prior the initiation of the therapeutic regimen.

If these results could be confirmed by more rigorous investigations, it may be hypothesized that the balance 5-HT/NA may modulate the levels of IL-6. Consequently, IL-6 levels could be considered a potential marker of the Th1/Th2 balance. If this hypothesis can be confirmed by more rigorous study, we could say that the greater the NA-ergic component of antidepressant, the higher the shift of the Th1/Th2 balance toward a Th2-type response.

Elucidating the effect of 5-HT/NA and Th1/Th2 balances on IL-6 levels and demonstrating IL-6 levels as a reliable marker of antidepressant response, may lead to further insights into the understanding of the pathophysiology of depression and antidepressant response even for classes of drugs different from the proven clinically effective, mainly serotonergic agents.

Authors’ contributions

MM conceived the study; MF wrote the main manuscript and performed the statistical analysis. GP and SC served as study consultants. FB carried out the immunological testing. All authors approved the final manuscript.

Disclosure

The authors received no financial support for this paper and have no conflict of interest to declare.

References

17. Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of 
18. Trivedi MH, Desaih D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ. Clinical evidence for serotonin and norepinephrine reuptake inhibition of 
20. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J. Training and 
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg 
429–435.
interleukin-6 activity, acute phase proteins, and function of the hypo- 
27. Kubera M, Kenis G, Bosmans E, et al. Plasma levels of interleukin-6, 
interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol. 
28. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, 
Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizo- 
30. Xia Z, DePierre JW, Nassberger L. Tricyclic antidepressants inhibit 
IL-6, IL-1 beta and TNF-alpha release in human blood monocytes and 
IL-2 and interferon-gamma in T cells. Immunopharmacology. 1996; 
370–379.
33. Wang W, Danielsson A, Svanberg E, Lundholm K. Lack of effects by 
34. Shen Y, Connor TJ, Nolan Y, Kelly JP, Leonard BE. Differential 
effect of chronic antidepressant treatments on lipopolysaccharide-
interferon-gamma-induced microglial production of IL-6 and nitric 
36. Elenkov IJ, Chrousos GP. Stress Hormones, Th1/Th2 patterns, 